171 related articles for article (PubMed ID: 38868532)
1. State-of-the-art cytometry in the search of novel biomarkers in digestive cancers.
G de Castro C; G Del Hierro A; H-Vázquez J; Cuesta-Sancho S; Bernardo D
Front Oncol; 2024; 14():1407580. PubMed ID: 38868532
[TBL] [Abstract][Full Text] [Related]
2. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
[TBL] [Abstract][Full Text] [Related]
3. Mammography screening: A major issue in medicine.
Autier P; Boniol M
Eur J Cancer; 2018 Feb; 90():34-62. PubMed ID: 29272783
[TBL] [Abstract][Full Text] [Related]
4. Biomarker discovery and validation for gastrointestinal tumors: A comprehensive review of colorectal, gastric, and liver cancers.
Hakami ZH
Pathol Res Pract; 2024 Mar; 255():155216. PubMed ID: 38401376
[TBL] [Abstract][Full Text] [Related]
5. Assessment of clinically related outcomes and biomarker analysis for translational integration in colorectal cancer (ACROBATICC): study protocol for a population-based, consecutive cohort of surgically treated colorectal cancers and resected colorectal liver metastasis.
Søreide K; Watson MM; Lea D; Nordgård O; Søreide JA; Hagland HR;
J Transl Med; 2016 Jun; 14(1):192. PubMed ID: 27357108
[TBL] [Abstract][Full Text] [Related]
6. The era of biomarkers and precision medicine in colorectal cancer: an interview with Ajay Goel.
Goel A
Epigenomics; 2022 Mar; 14(6):345-349. PubMed ID: 35081730
[TBL] [Abstract][Full Text] [Related]
7. Multiparametric analysis of colorectal cancer immune responses.
Leman JK; Sandford SK; Rhodes JL; Kemp RA
World J Gastroenterol; 2018 Jul; 24(27):2995-3005. PubMed ID: 30038466
[TBL] [Abstract][Full Text] [Related]
8. Clinical Applications of Flow Cytometry in Cancer Immunotherapies: From Diagnosis to Treatments.
Mishra HK
Methods Mol Biol; 2023; 2593():93-112. PubMed ID: 36513926
[TBL] [Abstract][Full Text] [Related]
9. Bibliometric study of immunotherapy for hepatocellular carcinoma.
Li Z; Zhang Y; Zhang B; Guo R; He M; Liu ZL; Yang L; Wang H
Front Immunol; 2023; 14():1210802. PubMed ID: 37600802
[TBL] [Abstract][Full Text] [Related]
10. Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma.
Ji JH; Ha SY; Lee D; Sankar K; Koltsova EK; Abou-Alfa GK; Yang JD
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108802
[TBL] [Abstract][Full Text] [Related]
11. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours.
Neuzillet C; de Mestier L; Rousseau B; Mir O; Hebbar M; Kocher HM; Ruszniewski P; Tournigand C
Pharmacol Ther; 2018 Jan; 181():49-75. PubMed ID: 28723416
[TBL] [Abstract][Full Text] [Related]
12. Molecular functions of microRNAs in colorectal cancer: recent roles in proliferation, angiogenesis, apoptosis, and chemoresistance.
Ellakwa DE; Mushtaq N; Khan S; Jabbar A; Abdelmalek MA; Wadan AS; Ellakwa TE; Raza A
Naunyn Schmiedebergs Arch Pharmacol; 2024 Apr; ():. PubMed ID: 38619588
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitin‑conjugating enzymes as potential biomarkers and therapeutic targets for digestive system cancers (Review).
Lei X; Hu X; Lu Q; Fu W; Sun W; Ma Q; Huang D; Xu Q
Oncol Rep; 2023 Mar; 49(3):. PubMed ID: 36799184
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors.
Zeng Z; Yang B; Liao Z
Front Oncol; 2021; 11():650481. PubMed ID: 33777812
[TBL] [Abstract][Full Text] [Related]
15. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
16. Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers.
Saoudi González N; Castet F; Élez E; Macarulla T; Tabernero J
Front Oncol; 2022; 12():1021772. PubMed ID: 36300092
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?
Huyghe N; Baldin P; Van den Eynde M
Gastroenterol Rep (Oxf); 2020 Feb; 8(1):11-24. PubMed ID: 32104582
[TBL] [Abstract][Full Text] [Related]
18. The Functions of EphA1 Receptor Tyrosine Kinase in Several Tumors.
Wu Y; Du Z; Mou J; Qiu X; Chen J; Cai S; Ren D; Xiao F; Zhou G; Yuan C
Curr Med Chem; 2023; 30(20):2340-2353. PubMed ID: 35996244
[TBL] [Abstract][Full Text] [Related]
19. Cancer/testis antigens: promising immunotherapy targets for digestive tract cancers.
Ai H; Yang H; Li L; Ma J; Liu K; Li Z
Front Immunol; 2023; 14():1190883. PubMed ID: 37398650
[TBL] [Abstract][Full Text] [Related]
20. Utilizing biomarkers in colorectal cancer: an interview with Ajay Goel.
Goel A
Future Oncol; 2017 Dec; 13(28):2511-2514. PubMed ID: 29168653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
